KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Short term Debt (2017 - 2023)

Historic Short term Debt for Bionano Genomics (BNGO) over the last 5 years, with Q3 2023 value amounting to $10.0 million.

  • Bionano Genomics' Short term Debt rose 749.22% to $10.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $10.0 million, marking a year-over-year increase of 749.22%. This contributed to the annual value of $9.4 million for FY2022, which is N/A changed from last year.
  • As of Q3 2023, Bionano Genomics' Short term Debt stood at $10.0 million, which was up 749.22% from $10.0 million recorded in Q2 2023.
  • Bionano Genomics' 5-year Short term Debt high stood at $20.1 million for Q4 2019, and its period low was $799815.0 during Q2 2019.
  • For the 4-year period, Bionano Genomics' Short term Debt averaged around $10.4 million, with its median value being $9.7 million (2023).
  • As far as peak fluctuations go, Bionano Genomics' Short term Debt soared by 164265.3% in 2020, and later soared by 749.22% in 2023.
  • Over the past 4 years, Bionano Genomics' Short term Debt (Quarter) stood at $20.1 million in 2019, then dropped by 29.11% to $14.2 million in 2020, then crashed by 34.11% to $9.4 million in 2022, then increased by 6.59% to $10.0 million in 2023.
  • Its last three reported values are $10.0 million in Q3 2023, $10.0 million for Q2 2023, and $9.5 million during Q1 2023.